ZELSUVMI Drug Patent Profile
✉ Email this page to a colleague
When do Zelsuvmi patents expire, and what generic alternatives are available?
Zelsuvmi is a drug marketed by Lnhc and is included in one NDA. There are fourteen patents protecting this drug.
This drug has fifty-six patent family members in nine countries.
The generic ingredient in ZELSUVMI is berdazimer sodium. Additional details are available on the berdazimer sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Zelsuvmi
Zelsuvmi will be eligible for patent challenges on January 5, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 5, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ZELSUVMI
| International Patents: | 56 |
| US Patents: | 14 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | ZELSUVMI at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZELSUVMI
Generic Entry Date for ZELSUVMI*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
GEL;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for ZELSUVMI
ZELSUVMI is protected by twenty-two US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZELSUVMI is ⤷ Try a Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ZELSUVMI
Topical compositions and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS
Topical compositions and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS WHERE ONE COMPONENT INCLUDES A NITRIC OXIDE RELEASING COMPOUND
Topical compositions and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS WHERE ONE COMPONENT INCLUDES WATER
Anhydrous compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Topical antiviral compositions and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF ADMINISTERING A NITRIC OXIDE RELEASING API IN A COMBINATION TOPICAL COMPOSITION
Topical antiviral compositions and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API
Topical antiviral compositions and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING AND/OR PREVENTING MOLLUSCUM CONTAGIOSUM WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API
Topical antiviral compositions and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF PREVENTING AND/OR REDUCING APPEARANCE AND/OR SIZE OF MALIGNANT LESION WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API
Topical gels and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Topical antiviral compositions, delivery systems, and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING AND/OR PREVENTING MOLLUSCUM CONTAGIOSUM WITH A NITRIC OXIDE RELEASING TOPICAL COMPOSITION
Topical antiviral compositions, delivery systems, and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING, PREVENTING, OR REDUCING LESIONS CAUSED BY MOLLUSCUM CONTAGIOSUM
Topical antiviral compositions, delivery systems, and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION WITH A TOPICAL NITRIC OXIDE RELEASING COMPONENT
Topical antiviral compositions, delivery systems, and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION USING A NITRIC OXIDE RELEASING ACTIVE INGREDIENT
Topical compositions and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF ADMINISTERING A NITRIC OXIDE RELEASING ACTIVE PHARMACEUTICAL INGREDIENT TO TREAT AND/OR PREVENT VIRAL INFECTION
Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Topical compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF APPLICATION OF TOPICAL PHARMACEUTICAL COMPOSITION TO TREAT DERMATOLOGICAL CONDITION
Topical gels and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Topical gels and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING SKIN AILMENT WITH NITRIC OXIDE RELEASING MACROMOLECULES AND HYDROPHILIC GEL
Topical compositions and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF APPLYING RELEASED NITRIC OXIDE TO SKIN FROM COMBINATION INCLUDING ANHYDROUS ALCOHOL GEL
Topical compositions and methods of using the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF INCREASING RELEASE OF NITRIC OXIDE FROM ANHYDROUS ALCOHOL GEL
FDA Regulatory Exclusivity protecting ZELSUVMI
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Lnhc | ZELSUVMI | berdazimer sodium | GEL;TOPICAL | 217424-001 | Jan 5, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZELSUVMI
See the table below for patents covering ZELSUVMI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2961382 | COMPOSITIONS TOPIQUES ET LEURS PROCÉDÉS D'UTILISATION (TOPICAL COMPOSITIONS AND METHODS OF USING THE SAME) | ⤷ Try a Trial |
| Canada | 2606565 | PARTICULES LIBERANT DE L'OXYDE NITRIQUE POUR THERAPIE A BASED'OXYDE NITRIQUE ET APPLICATIONS BIOMEDICALES (NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS) | ⤷ Try a Trial |
| Brazil | 112014000178 | composições tópicas | ⤷ Try a Trial |
| Japan | 2008545714 | ⤷ Try a Trial | |
| Japan | 6944487 | ⤷ Try a Trial | |
| Japan | 5274248 | ⤷ Try a Trial | |
| European Patent Office | 3698775 | COMPOSITIONS ANTIVIRALES TOPIQUES ET MÉTHODES D'UTILISATION (TOPICAL ANTIVIRAL COMPOSITIONS AND METHODS OF USING THE SAME) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
